Cancer Clinical Trials

Breast

  • Alliance A011202 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

  • CINJ 040406-4862 - Effect of DNA Variations on Breast Cancer Risk and Recurrence

  • CINJ 130404 - Women’s Circle of Health Study (Breast Cancer Study in African American Women)

  • ECOG 2112 - A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer

  • Novartis CLEE011A2301 - A Randomized Double-Blind, Placebo-Controlled Study of LEE011 In Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer Who Received No Prior Therapy For Advanced Disease (Closed to Enrollment, Effective February 6, 2015)

  • Novartis CLEE011E2301 - A Phase III Randomized, Double-Blind, Placebo-Controlled Study of LEE011 Or Placebo in Combination With Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer (Closed to Enrollment)

  • Novartis CLEE011F2301 - A Randomized Double-Blind, Placebo Controlled Study of Ribociclib In Combination With Fulvestrant for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer Who Have Received No Or Only One Line Of Prior Endocrine Treatment (Monaleesa-3)(Closed to Enrollment)

  • Puma 3144A2-3004-WW - A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer (Closed to Enrollment)

  • Puma Puma-NER-6201 - An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

  • RCINJ 041401 - A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients with ER, PR, HER2 Negative Breast Cancer (TNBC)

  • RTOG 1304 - A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Digestive/Gastrointenstinal

  • BMS CA209-577 - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

  • Gilead GS-US-296-1080 - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  • RTOG 1112 - Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma

Genetics

  • ECOG-ACRIN EAY-131 - A Trial That Aims to Establish Whether Patients With Tumor Mutations, Amplifications Or Translocations in One of the Genetic Pathways of Interest Are Likely to Derive Clinical Benefit If Treated With Agents Targeting That Specific Pathway In A Single-Arm Design

Genitourinary

  • Bayer REASSURE - Radium-223 Alpha Emitter Agent in Non-Intervention Safety Study in mCRPC Population for Long-Term Evaluation

  • RCINJ 131023 (COUPLES) - Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer

  • RCINJ 131107 (PROGRESS) - Randomized Controlled Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors PROGRESS – PRostate Cancer Online Guide & Resources for Electronic Survivorship Service)

Gynecologic

  • GOG 0225 - Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube And Primary Peritoneal Cancer Progression-Free Survival?

Head and Neck

  • Galera GT-201 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis (OM) in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Hematologic/Blood

  • Pharmacyclics PCYC-1134M-CA - informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

Other

  • Accuray ReCKord - CyberKnife Registry Protocol

  • RCINJ 001209 (PRECISION) - Targeted Genomic Analysis of Human Cancer

Respiratory/Thoracic

  • Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

  • JoLT-Ca STU 022015-069 - A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

  • Oncocyte PRO068 - A Study to Evaluate a Panel of Blood Biomarkers For Use In Patients Undergoing Evaluation For Lung Cancer, ONC-LN-04

  • OSE Pharma OSE2101C301 - A Randomized Parallel Group Phase III Trial of OSE 2101 as 2nd Line After Prior Platinum-Based Chemotherapy Failure or as 3rd Line After Platinum-Failure and Checkpoint Inhibitor-Failure, Compared With Standard Treatment (Docetaxel or Pemetrexed) In HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable For Radiotherapy or Metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

  • SWOG S1400 - Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (LUNG-MAP)

Skin

  • ECOG-ACRIN 6134 - A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab At Progression vs. Ipilimumab + Nivolumab Followed By Dabrafenib + Trametinib At Progression in Patients With Advanced BRAFV600 Mutant Melanoma